Rhythm Pharmaceuticals (RYTM) Gross Profit (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Gross Profit data on file, last reported at $53.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $53.0 million, up 82.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $194.2 million (up 58.3% YoY), and the FY2025 annual result was $170.3 million, up 45.83% from the prior year.
• Gross Profit advanced to $53.0 million in Q1 2026 per RYTM's latest filing, from $52.5 million in the prior quarter.
• Over five years, Gross Profit peaked at $53.0 million in Q1 2026 and troughed at -$9.1 million in Q4 2022.
• A 5-year average of $24.3 million and a median of $23.2 million in 2024 frame the typical range for Gross Profit.
• On a YoY basis, Gross Profit climbed as much as 6241.61% in 2022 and fell as far as 674.07% in 2022.
• A 5-year view of Gross Profit shows it stood at -$9.1 million in 2022, then surged by 331.39% to $21.0 million in 2023, then soared by 81.15% to $38.0 million in 2024, then jumped by 37.87% to $52.5 million in 2025, then gained by 0.96% to $53.0 million in 2026.
• Business Quant data shows RYTM's Gross Profit at $53.0 million in Q1 2026, $52.5 million in Q4 2025, and $45.8 million in Q3 2025.